Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...
A shareholder class action lawsuit has been filed against Replimune Group, Inc. (“Replimune”) (NASDAQ: REPL). The lawsuit ...
After two rejections and layoffs that eliminated more than 200 jobs, Massachusetts biotech Replimune Group finally secured ...
XDA Developers on MSN
After a week in Zed, I couldn't go back to how slow Cursor had become
Zed is a speed demon you can't ignore.
Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are ...
2026年6月2日，全球支付技术公司Visa宣布完成对云端编程平台Repl.it的战略投资。此次投资旨在加强双方在技术领域的合作，推动在线编程教育与创新应用的发展。 Repl.it是美国一家基于云端的程序语言在线交互式平台，用户可以直接在浏览器上学习和体验各种编程 ...
Replimune Group, Inc.'s RP1 has failed at the FDA twice, but Makary's resignation keeps a resubmission possible. REPL's cash runway stands at under a year; workforce cuts and RP1 discontinuation are ...
This project is a proof-of-concept that runs a JavaScript engine inside a web browser by compiling it to WebAssembly. The engine is Goja — a pure-Go implementation of ECMAScript 5.1 — and the ...
FDA has now rejected Replimune’s melanoma immunotherapy RP1 on two separate occasions The drug was under consideration for use with Bristol Myers Squibb’s (BMY) Opdivo therapy Regulators maintained ...
The JavaScript innovation train is really picking up momentum lately, driven—as always—by the creativity of the JavaScript developer community. The emerging local-first SQL datastores crystalize ideas ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果